News

While AAN makes a push for annual cognitive assessments in older adults, the USPSTF found that there is not enough evidence to support routine screening.

Analysis suggests that high-intensity aerobic exercise intervention, when gamified and delivered in an at-home fashion, can attenuate the symptoms of Parkinson disease while maintaining good adherence.

The neurologist at the National MS Center and University Hospital, in Brussels, spoke to the decision-making process when treating women with MS who seek to get pregnant, or who are planning a family.

Data to be presented at the 2019 European Pediatric Neurology Society Congress suggest Zolgensma (onasemnogene abeparvovec-xioi) is associated with major milestone gains in SMA type 1.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for adult neurologists to ensure a smooth transition of care for patients with epilepsy entering their care.

The prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.

A prospective, cross-sectional assessment suggests that patients with DMD can be adequately assessed for cognition in a brief period of time using the NIHTB‐CB, and additionally suggested a cognitive vulnerability in mothers who were carriers of DMD mutation.

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet discussed the evolving understanding of the blood-brain barrier in MS, and what might still be left to uncover.

Further analysis of the SHINE trial suggest nusinersen is linked to 6-year maintained improvement in patients with SMA. Biogen has announced a new global trial of a 50 mg loading dose in a broader cohort.

In a time where more than half of all patients with acute stroke and most patients with severe stroke arrive at the hospital via emergency medical services, a study suggests mobile stroke units are better equipped to accurately triage patients.

Mallinckrodt’s repository corticotropin injection was shown to have a lower cost per patient response compared to other late-line treatments for multiple sclerosis relapses, costing an estimated $148,528 less per response.

The professor of medicine, neurology, at the University of Toronto discussed the best ways for pediatric neurologists to ensure a smooth transition of care for patients with epilepsy who are leaving the pediatric system.

The GeNeuro agent showed marked reductions in brain atrophy in the thalamus and cerebral cortex through a long-term extension period treating patients with multiple sclerosis.

The 1st Annual Congress on the Future of Neurology will take place September 27-28, 2019 at the InterContinental New York Times Square in New York City.

Wave Life Sciences intends to file for accelerated approval in the second half of 2020 pending muscle biopsy results from an open-label extension study.

The director of the adult epilepsy center at Washington University in St. Louis discussed the takeaways for clinicians regarding the use of intranasal diazepam as a treatment for runs of seizures in patients with refractory epilepsy.

Impel NeuroPharma's nasal dihydroergotamine mesylate acute migraine therapy INP104 has shown excellent pharmacokinetic data, and is set to be assessed in a 24-week trial with a planned 28-week extension.

The director of the Sagol Center for Hyperbaric Medicine and Research spoke about how hyperbaric oxygen therapy may offer new hope in improving cognition in patients who have had a stroke.

The professor and senior physician in the department of clinical neuroscience at the Karolinska Institutet spoke to the aspects of MS—such as brain volume loss—which are not currently being addressed by the available disease-modifying therapies.

According to new data from STRIVE, 75.4% of those treated with natalizumab achieved overall No Evidence of Disease Activity status by year 4, and no patients had incidence of progressive multifocal leukoencephalopathy.

Montefiore Health System will also be working with The American Journal for Managed Care.

Neurology News Network for the week ending September 14, 2019.

After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.

Nearly 87% of patients enrolled in the phase 3b CASTING study had no evidence of disease activity following treatment with ocrelizumab after having an inadequate response to prior DMTs.

The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.

The global head of neuroimmunology at Genentech spoke about the wealth of data being presented on its anti-CD20 monoclonal antibody ocrelizumab, as well as the success thus far in trials of its NMOSD agent, satralizumab.

Study coauthor and professor of neurology and ophthalmology at the University of Colorado provides insight into phase 3 study results of satralizumab, presented at ECTRIMS 2019.

The professor of epidemiology and nutrition at Harvard TH Chan School of Public Health discussed what might be an optimal dose of vitamin D supplementation in MS, and how vitamin D deficiency should be addressed as a modifiable risk factor.

New phase 3 data from the OPTIMUM head-to-head trial show that 20-mg ponesimod resulted in a significantly lower annualized relapse rate in adults with multiple sclerosis compared to 14-mg teriflunomide at 108 weeks.

The humanized monoclonal antibody was particularly effective in patients who were seropositive for aquaporin-4 autoantibodies.